Association of MDR1 gene polymorphisms with susceptibility to Hepatocellular carcinoma in the chinese population

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5451-5454

  Ren, Yong Qiang ^a   Han, Ju Qiang ^a   Cao, Jian Biao ^a   Ji, Shao Xiang ^a   Fan, Gong Ren ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Association analysis; HCC; Multidrug resistance 1 gene; Single nucleotide polymorphisms; Susceptibility

Indexed keywords

EID: 84874072641     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5451     Document Type: Article

References (33)

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al (2003). P-glycoprotein: from genomics to mechanism. Oncogene, 22, 7468-85.
2. Bosch FX, Ribes J, Diaz M, et al (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, S5-16.
3. But DY, Lai CL, Yuen MF (2008). Natural history of hepatitisrelated hepatocellular carcinoma. World J Gastroenterol, 14, 1652-6.
4. Cavaco I, Gil JP, Gil-Berglund E, et al (2003). CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med, 41, 1345-50.
5. Chen JG, Zhang SW, Chen WQ (2010). Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004 - 2005. Zhonghua Yu Fang Yi Xue Za Zhi, 44, 383-9 (in Chinese).
6. Chen XJ, Wang XG, Shen YJ, et al (2011). Correlation of MDR1 single nucleotide polymorphism with prognosis of hepatocellular carcinoma. J Chin Oncol, 17, 209-211.
7. Chen YD, Yang F, Feng ST, et al (2009). A case-control study on the association between genetic polymorphisms of MDR1 and hepatic cell cancer susceptibility. Chin Clin Oncol, 14, 1077-81.
8. Chinn LW, Kroetz DL (2007). ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther, 81, 265-9.
9. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.
10. Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8.
11. Haliassos A, Chomel JC, Tesson L, et al (1989). Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res, 17, 3606.
12. meyer S,Burk O,von Richter O,et al (2000).Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 97, 3473-8.
13. Jamroziak K, Mlynarski W, Balcerczak E, et al (2004). Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol, 72, 314-21.
14. Kaya P, Gunduz U, Arpaci F, et al (2005). Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol, 80, 26-34.
15. Kurzawski M, Drozdzik M, Suchy J, et al (2005). Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol, 61, 389-94.
16. Leonessa F, Clarke R (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer, 10, 43-73.
17. Llovet JM, Burroughs A, Bruix J (2003). Hepatocellular carcinoma. Lancet, 362, 1907-17.
18. Nault JC, Zucman-Rossi J (2011). Genetics of hepatobiliary carcinogenesis. Semin Liver Dis, 31, 173-87.
19. Parikh S, Hyman D (2007). Hepatocellular cancer: a guide for the internist. Am J Med, 120, 194-202.
20. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
21. Pechandova K, Buzkova H, Slanar O, et al (2006). Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha), 52, 184-9.
22. Sohn JW, Lee SY, Lee SJ, et al (2006). MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol, 36, 137-41.
23. Suriawinata A, Xu R (2004). An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis, 24, 77-88.
24. Taniguchi S, Mochida Y, Uchiumi T, et al (2003). Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther, 2, 1351-9.
25. Thorgeirsson SS, Grisham JW (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 31, 339-46.
26. Vander Borght S, Komuta M, Libbrecht L, et al (2008). Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int, 28, 1370-80.
27. Wu L, Xu X, Shen J, et al (2007). MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol, 96, 62-8.
28. Yu X, Xie H, Wei B, et al (2011). Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS One, 6, e25933.
29. Yuan ZR, Chu GY, Dan Y, et al (2012). BRCA1: a new candidate gene for bovine mastitis and its association analysis between single nucleotide polymorphisms and milk somatic cell score. Mol Biol Rep, 39, 6625-6631.
30. Yuan Z, Li J, Li J, et al (2012). Effects of DGAT1 gene on meat and carcass fatness quality in Chinese commercial cattle. Mol Biol Rep, DOI 10.1007/s11033-11012-12251-11032.
31. Yuan Z, Li J, Li J, Gao X, Xu S (2013). SNPs identification and its correlation analysis with milk somatic cell score in bovine MBL1 gene. Mol Biol Rep, 40, 7-12.
32. Yuan ZR, Li J, Zhang LP, et al (2012). Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle. Gene, 505, 190-4.
33. Zeng X, Liu S, Yu H, et al (2012). DNA repair capacity, DNAstrand break repair gene polymorphisms, and the incidence of hepatocellular carcinoma in southwestern Guangxi of China. DNA Cell Biol, 31, 1384-91.